|

Ciltacabtagene Autoleucel Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: Autologous Anti-B-cell maturation antigen (BCMA) CAR-T Cells JNJ-68284528, Autologous Anti-BCMA CAR-T Cells JNJ-68284528, Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528, Autologous Bi-epitope CAR T-cells JNJ-68284528, CARVYKTI, Carvykti, Cilta-cel, JNJ 68284528, JNJ-68284528, JNJ68284528, LCAR B38M, LCAR-B38M, LCAR-B38M-transduced CAR-T Cells JNJ-68284528, LCARB38M, cilta-cel

Other1 trial

The Norwegian Immunotherapy in Multiple Myeloma Study

Rochester, Minnesota1 trial

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic in Rochester

Phase 2

St Louis, Missouri1 trial

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Washington University School of Medicine

Phase 1

Milwaukee, Wisconsin1 trial

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Froedtert & the Medical College of Wisconsin

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.